XML 45 R28.htm IDEA: XBRL DOCUMENT v3.20.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Options Valuation Assumptions
The assumptions that the Company used to determine the grant-date fair value of options granted to employees and directors were as follows, presented on a weighted-average basis:

December 31,

2019

2018

Risk-free interest rate1.68 %

2.87 %

Expected term (in years)6.0

6.1

Expected volatility62.2 %

58.4 %

Expected dividend yield%

%


The assumptions that the Company used to determine the fair value of options granted to non-employees were as follows, presented on a weighted-average basis:

December 31,

2019

2018

Risk-free interest rate1.68 %

2.87 %

Expected term (in years)6.0

9.7

Expected volatility62.2 %

58.4 %

Expected dividend yield%

%

Schedule of Stock Option Activity The following table summarizes option activity under the 2017 Plan since December 31, 2018 (in thousands, except share and per share amounts):

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 201847,735  

$0.66  

9.5

$121  
Granted2,330,739  

$8.18  


Outstanding December 31, 20192,378,474  

$8.03  

9.7

$6,722  
Options vested or expected to vest as of December 31, 20192,378,474  

$8.03  

9.7

$6,722  
Options exercisable as of December 31, 2019111,633  

$4.98  

9.2

$656  
Schedule of Restricted Stock Activity
The following table summarizes restricted stock activity since December 31, 2017:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 201791,680  $0.30  
Granted92,497  $0.72  
Vested(51,532) $0.30  
Unvested restricted common stock as of December 31, 2018132,645  $0.51  
Granted62,988  $5.22  
Vested(195,633) $5.94  
Unvested restricted common stock as of December 31, 2019—  $—  
Schedule of Stock-Based Compensation
The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands):
December 31,

2019

2018
Research and development$3,171  

$62  
General and administrative472  

 

$3,643  

$63